Trials / Unknown
UnknownNCT05091125
Diagnostic Performance of the S100B Protein in the Prognosis of Patients With Mild Head Trauma With Risk of Complications in Patients Over 65 Years Old.
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (estimated)
- Sponsor
- University Hospital, Strasbourg, France · Academic / Other
- Sex
- All
- Age
- 62 Years
- Healthy volunteers
- Not accepted
Summary
For patients with mild head trauma, a large number of CT scans are performed. The S100B protein allows, when the dosage is below the threshold, to rule out the diagnosis of brain damage with a negative predictive value of 98%. In patients over 65 years old it was found that the dosage of S100B came back positive more often compared to a younger population. This study proposes to determine the positivity threshold value for S100B dosage in patients over 65 years old. In patients over 65 years suffering from mild head trauma, a head CT will systematically be performed (in accordance with the recommendations) and the S100B will be measured (taken from an additional tube on the blood test carried out in these patients). The results of the TDM will then be compared with the results of the S100B to determine the values of sensitivity, specificity, negative and positive predictive value of different thresholds.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Diagnostic performance of the S100B protein dosage | Dosage of the S100B protein in patients with mild head trauma with complication risks |
Timeline
- Start date
- 2021-11-02
- Primary completion
- 2024-11-02
- Completion
- 2024-11-02
- First posted
- 2021-10-25
- Last updated
- 2021-10-25
Source: ClinicalTrials.gov record NCT05091125. Inclusion in this directory is not an endorsement.